Vyvanse Capsules Specified Drug Use-results Survey (Surveillance regarding pediatric long-term use)

Vyvanse Capsules Specified Drug Use-results Survey (Surveillance regarding pediatric long-term use) - Vyvanse Capsules Specified Drug Use-results Survey (Surveillance regarding pediatric long-term use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039018

Enrollment

1500

Registered

2020-01-06

Start date

2020-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit/hyperactivity disorder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with attention deficit/hyperactivity disorder (AD/HD) between 6 and 18 years of age without prior exposure to Vyvanse Capsules.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
(1) Safety Incidence rates of adverse drug reactions, Safety specification items of Vyvanse Capsules (2) Efficacy Evaluation of physicians by the ADHD Rating Scale IV (ADHD RS-IV) Japanese Version	—

Countries

Japan

Contacts

Public ContactKouji Yamashita

Takeda Pharmaceutical Co., Ltd. PMS Strategic Management, Japan Medical Office

kouji.yamashita@takeda.com+81-80-4324-2955

Outcome results